EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Real-World Risk of Venous Thromboembolism with Bevacizumab Biosimilar versus Reference Biologic in Japanese Patients with Cancer: A Retrospective Cohort Study

Nobuhiro Ooba, Ryoko Sakai, Keiko Sekine, Yui Kanno, Osamu Ishizuka, Takayuki Hirai, Hiroya Taniguchi

Oncology and Therapy · 19.11.2026

DOI: 10.1007/s40487-026-00473-4 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Oncology and Therapy, online erschienen am 19.11.2026. Verfasst von Nobuhiro Ooba und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacoepidemiology, Nihon University School of Pharmacy, Funabashi, Chiba, Japan. ooba.nobuhiro@nihon-u.ac.jp. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nippon Kayaku.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

BevacizumabBiosimilarsCohort studiesReal-world evidenceSafetyVenous thromboembolism

Autor:innen und Institutionen

  • Department of Pharmacoepidemiology, Nihon University School of Pharmacy, Funabashi, Chiba, Japan. ooba.nobuhiro@nihon-u.ac.jp.
  • Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.
  • Quality and Pharmacovigilance Division, Pharmaceuticals Group, Nippon Kayaku Co., Ltd, Chiyoda, Tokyo, Japan.
  • Clinical Development & Medical Affairs Division, Pharmaceuticals Group, Nippon Kayaku Co., Ltd, Chiyoda, Tokyo, Japan.
  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.

Förderung

  • Nippon Kayaku

Zitieren

APA

Ooba, N., Sakai, R., Sekine, K., Kanno, Y., Ishizuka, O., Hirai, T., & Taniguchi, H. (2026). Real-World Risk of Venous Thromboembolism with Bevacizumab Biosimilar versus Reference Biologic in Japanese Patients with Cancer: A Retrospective Cohort Study. Oncology and Therapy. https://doi.org/10.1007/s40487-026-00473-4

Vancouver

Ooba N, Sakai R, Sekine K, Kanno Y, Ishizuka O, Hirai T, et al. Real-World Risk of Venous Thromboembolism with Bevacizumab Biosimilar versus Reference Biologic in Japanese Patients with Cancer: A Retrospective Cohort Study. Oncology and Therapy. 2026. doi:10.1007/s40487-026-00473-4

BibTeX
@article{Ooba2026,
  author = {Ooba, Nobuhiro and Sakai, Ryoko and Sekine, Keiko and Kanno, Yui and Ishizuka, Osamu and Hirai, Takayuki and Taniguchi, Hiroya},
  title = {Real-World Risk of Venous Thromboembolism with Bevacizumab Biosimilar versus Reference Biologic in Japanese Patients with Cancer: A Retrospective Cohort Study},
  journal = {Oncology and Therapy},
  year = {2026},
  doi = {10.1007/s40487-026-00473-4}
}
Kostenlos starten →